

SASTASUNDAR VENTURES LIMITED

Azimganj House, 2nd floor,
7 Abanindra Nath Thakur Sarani (Formerly Camac Street),
Kolkata – 700017, India. Tel: +91 33 2282 9330; Fax: +91 33 2282 9335
Email: info@sastasundar.com; Website: www.sastasundarventures.com
CIN: L65993WB1989PLC047002

Date: 07-02-2026

To
The General Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Tower
Dalal Street, Mumbai - 400 001

Manager - Listing
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Mumbai - 400 051

Ref: Script Code: 533259 and Symbol: SASTASUNDR

Sub: Publication of Unaudited Financial Results for the quarter and nine months ended 31st December, 2025 in the Newspapers

Dear Sir/ Madam,

We are enclosing herewith the copies of Newspaper Publication of the Unaudited Financial Results of the Company for the quarter and nine months ended 31st December, 2025 as published in Business Standard (English Newspaper) and Ek Din (Bengali Newspaper) on 7th February, 2026 in terms of Regulation 47 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

This is for your information and record.

Thanking you,

For **Sastasundar Ventures Limited**

Pratap Singh
Company Secretary and Compliance Officer

Encl: As Above

OFFICE OF THE NAGAR PANCHAYAT ARJUNDA, DISTT- BALOD (C.G.)
NOTICE INVITING TENDER (1ST CALL)
 Main Portal: <https://eproc.cgstate.gov.in>
 SYSTEM TENDER NO.: 185170, NIT NO. 2011 Dated 04/02/2026
 Online tender are invited by the Chief Municipal Officer, Nagar Panchayat, Arjunda for the following work in Form "F" for lump sum contract from the contractors registered with Unified Registration System (Single Window) on GoCG PWD & e-Procurement System Portal (<https://eproc.cgstate.gov.in>) as per the 'Key Dates' mentioned below. All other conditions for submission of tenders and criteria for prequalification etc. have been mentioned in the tender documents.

SYSTEM TENDER No.	NAME OF WORK	PROBABLE AMOUNT OF CONTRACT	BID DUE DATE
185170	Design, Construction, Testing, Commissioning of All The Components of Interception and Diversion Based Sewage Treatment Plant (STP) Work Including 05 Years of Operation and Maintenance of The Entire System in Nagar Panchayat, Arjunda under SBM 2.0	239.22 Lakh	Date: 26.02.2026 Time: 17:00

The tender documents containing detailed terms & conditions are available for free download on GoCG e-Procurement portal <http://eproc.cgstate.gov.in> through sub portal of Urban Administration & Development Department <http://uad.cg.gov.in> Bidders have to quote online their prices along with Technical and commercial bids in prescribed formats on the above mentioned portal only.

Chief Municipal Officer
Nagar Panchayat Arjunda

THE KARUR VYSYA BANK LIMITED
 Regd. & Central Office, No. 20, Erode Road, Vadivel Nagar, L.N.S., Karur - 639002
 [CIN No: L65110TN1916PLC001295] [Website: www.kvb.bank.in]
 [E-mail: kvb_sig@kvbmail.com] [Tel No: 04324-269441]

Notice is hereby given that the following share certificate(s) issued by the Bank is reported as lost/misplaced and holder(s) of the said share certificate(s) have applied to the Bank to issue duplicate Share Certificate(s).

Folio No	Name of the Shareholder(s)	Certificate Numbers	Distinctive Numbers	No of Shares
P03356	PANKAJA LAKSHMI M	7098	20611536 - 20613575	2040
M05006	R. MEENAKSHI	2343	5129121 - 5143225	14105
		175209	728798316 - 728799725	1410

Any person who has any claim(s) in respect of the said shares should lodge such claim(s) with the Bank at its registered office within 15 days of publication of this notice else the Bank will proceed to issue Letter of Confirmation in lieu of duplicate share certificate to the aforesaid applicant(s) without any further intimation.

For The Karur Vysya Bank Limited
Srinivasarao M
 Company Secretary

Place : Karur
 Date : 06.02.2026

Sai Make it better together

Sai Life Sciences Limited
 CIN: L24110TG1999PLC030970
 Plot No. DS-7, IKP Knowledge Park, Turkapally (V), Shameerpet Mandal, Medchal-Malkajgiri (Dist), Hyderabad -500078, Telangana, India.
 T: +91 40 6815 6000 | F: +91 40 6815 6199 | E: investors@sailife.com | W: www.sailife.com

STATEMENT OF UN-AUDITED FINANCIAL RESULTS
FOR THE THIRD QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

The Board of Directors of the Company at their meeting held on February 05, 2026, approved the Un-audited Financial Results of the Company, for the third quarter and nine months ended December 31, 2025.

The results, along with the Limited Review Report, have been posted on the Company's website at <https://www.sailife.com> and can be accessed by scanning the QR code.

By the order of the Board
For Sai Life Sciences Limited

Sd/-
Krishna Kanumuri
 Managing Director & CEO
 DIN: 00064614

For more information, please scan:



Date: February 07, 2026
 Place: Hyderabad

BEFORE THE NATIONAL COMPANY LAW TRIBUNAL, CHENNAI BENCH I
 CP (CAA) / 93 / 2025 IN CA (CAA) / 73 / (CHE) / 2025
 In the matter of the Companies Act, 2013

And
 In the Matter of Scheme of Amalgamation between AUGMENTO LABS PRIVATE LIMITED (Transferor Company), and SAKSOFT LIMITED (Transferee Company) and their respective Shareholders and Creditors

NOTICE OF HEARING OF PETITION
 A Petition under Sections 230 to 232 of the Companies Act, 2013 for an order sanctioning the Scheme of Amalgamation between Augmento Labs Private Limited (Transferor Company) and Saksoft Limited (Transferee Company) and their respective Shareholders and Creditors ('the Scheme'), was presented by the Transferor Company on 16-12-2025. The Petition was admitted by the Hon'ble NCLT, Chennai Bench I vide order dated 21-01-2026 and is fixed for hearing before the NCLT Chennai Bench I on the 11-03-2026.

Any person desirous of supporting or opposing the said Petition should send to the Petitioner Company's registered office situated at Global Infocity, Block-A, 2nd Floor, 40 MGR Salai, Kadanchavadi, Perungudi, Chennai, Tamil Nadu, India, 600096, a notice of his/her intention, signed by him/her or his/her advocate, with his/her name and address, so as to reach the Company, not later than two days before the date fixed for the hearing of the Petition. Where he/she seeks to oppose the petition, the grounds of opposition or a copy of his/her affidavit shall be furnished with such notice.

A copy of the Petition will be furnished by the undersigned to any person requiring the same on payment of the prescribed charges for the same.

MEERA VENKATRAMANAN
 Authorised Signatory

Place: Chennai
 Date: 07-02-2026

FORM NO. NCLT-3A
ADVERTISEMENT DETAILING PETITION [SEE RULE 35 OF THE NATIONAL COMPANY LAW TRIBUNAL RULES, 2016] IN THE MATTER OF SCHEME OF ARRANGEMENT OF
MERIDIAN MEDICAL RESEARCH & HOSPITAL LTD. (PETITIONER COMPANY NO. 1/ TRANSFEROR COMPANY) WITH NARAYANA HRUDAYALAYA LIMITED (PETITIONER COMPANY NO. 2/ TRANSFEREE COMPANY) AND THEIR RESPECTIVE SHAREHOLDERS AND CREDITORS COMPANY PETITION (CAA) NO. 03/BB/2026 CONNECTED WITH COMPANY APPLICATION (CAA) NO.44/BB/2025

MERIDIAN MEDICAL RESEARCH & HOSPITAL LTD. (CIN: U85110KA1995PLC207874)
 A Company registered under Companies Act of 1956 Having its registered office at No.258/A, Bommasandra Industrial Area, Anekal Taluk, Bangalore, Karnataka, India, 560099
Represented by Dr. Emmanuel Rupert, Authorized Signatory/Director ...Petitioner Company No. 1/ Transferor Company

NARAYANA HRUDAYALAYA LIMITED (CIN: L85110KA2000PLC027497)
 A Company registered under Companies Act of 1956 Having its registered office at No.258/A, Bommasandra Industrial Area, Anekal Taluk, Bangalore, Karnataka, India, 560099
Represented by Mr. Sridhar S, Authorized Signatory/Company Secretary ...Petitioner Company No. 2/ Transferor Company

(Together called as "Petitioner Companies")
NOTICE OF PETITION

A Joint Company Petition under Sections 230 to 232 of the Companies Act, 2013, seeking approval of Scheme of Arrangement of Meridian Medical Research & Hospital Ltd. with Narayana Hrudayalaya Limited and their respective shareholders and creditors ("Scheme") was presented by the Petitioner Companies on January 30, 2026, before the Hon'ble National Company Law Tribunal, Bengaluru Bench and the said petition is fixed for hearing before the Hon'ble Tribunal Bengaluru Bench on February 27, 2026.

Any person desirous of supporting or opposing the said petition should send to Mr. R. Inbaraju, Advocate and Authorized Representative of the Petitioner Companies, having his office at No. 10/28, "Shankaralaya" 2nd Floor, 3rd Cross Street, R. K. Nagar, Raja Annamalapuram, Mandaveli, Chennai - 600028; the notice to his/her intention, signed by him/her or his/her Advocate/Representative, with his/her name and address, so as to reach the Petitioner companies registered office not later than two (2) days before the date fixed for the hearing of the petition. Where he/she seeks to oppose the petition, the grounds of opposition or a copy of his/her affidavit shall be furnished with such notice. A copy of the petition will be furnished by the undersigned to any person requiring the same on payment of the prescribed charges for the same.

Meridian Medical Research & Hospital Ltd. ("Petitioner Company No.1/ Transferor Company") Sd/- Dr. Emmanuel Rupert, Authorized Signatory/Director	Narayana Hrudayalaya Limited ("Petitioner Company No.2/ Transferor Company") Sd/- Mr. Sridhar S, Authorized Signatory/ Company Secretary
---	--

Date: 07.02.2026
 Place: Bengaluru

SASTASUNDAR VENTURES LIMITED
 Corporate Identity No. (CIN) - L65993WB1989PLC047002
 Registered Office: Azimganj House, 2nd Floor, 7 Abanindra Nath Thakur Sarani (formerly Camac Street), Kolkata - 700 017
 Email: investors@sastasundar.com • Website: www.sastasundarventures.com • Phone - 033-2282 9330

EXTRACT OF THE STANDALONE AND CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2025
 (Rs. in Lacs except for EPS)

Particulars	Standalone						Consolidated					
	Quarter ended		Nine Months ended		Year ended		Quarter ended		Nine Months ended		Year ended	
	31-Dec-25	30-Sep-25	31-Dec-24	31-Dec-25	31-Dec-24	31-Mar-25	31-Dec-25	30-Sep-25	31-Dec-24	31-Dec-25	31-Dec-24	31-Mar-25
Total Income from Operations (Net)	9.46	9.78	10.72	28.91	30.09	40.40	34,573.70	30,132.06	28,129.05	94,548.58	82,511.41	111,095.46
Net Profit / (Loss) for the period before Tax and exceptional and extraordinary items	(40.99)	(27.98)	(10.49)	(79.92)	(64.54)	(71.37)	91.87	(1,847.11)	(3,700.87)	1,263.42	268.27	(223.19)
Net Profit / (Loss) for the period before tax (after exceptional and extraordinary items)	(40.99)	(27.98)	(10.49)	(79.92)	(64.54)	(71.37)	91.87	(1,863.72)	(3,924.19)	1,246.81	(18,822.64)	(19,286.10)
Net Profit / (Loss) for the period after tax (after exceptional and extraordinary items)	(40.99)	(27.98)	(10.49)	(79.92)	(64.54)	(71.37)	36.87	(1,543.93)	(4,002.52)	1,152.15	(14,031.11)	(12,273.90)
Total Comprehensive Income/ (Loss) for the period	(41.73)	(28.27)	(9.97)	(81.47)	(62.98)	(72.98)	51.11	(1,511.10)	(3,770.29)	1,223.52	(15,084.27)	(13,399.10)
Paid up Equity Share Capital (Face Value per share Rs.10)	3,181.05	3,181.05	3,181.05	3,181.05	3,181.05	3,181.05	3,181.05	3,181.05	3,181.05	3,181.05	3,181.05	3,181.05
Reserves (excluding Revaluation Reserve as shown in the Audited Balance sheet of the previous year)	-	-	-	-	-	23,999.48	-	-	-	-	-	63,806.05
Earnings per share (Basic)	(0.13)*	(0.09)*	(0.03)*	(0.25)*	(0.20)*	(0.22)	0.35 *	(3.99)*	(8.47)*	3.88 *	(32.96)*	(28.66)
Earnings per share (Diluted)	(0.13)*	(0.09)*	(0.03)*	(0.25)*	(0.20)*	(0.22)	0.35 *	(3.99)*	(8.47)*	3.88 *	(32.96)*	(28.66)

* Not annualised

Notes:
 1. The above is an extract of the detailed format of Standalone and Consolidated Quarterly Financial Results for the quarter and nine months ended December 31, 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the website of the Stock Exchange(s) www.bseindia.com and www.nseindia.com and also on the Company's webpage at https://www.sastasundarventures.com/Pdf/Unaudited_Financial_Results_Standalone_and_Consolidated_31122025.pdf and can also be accessed by scanning the following Quick Response (QR) code given below.
 2. Exceptional items adjusted in the statement of Profit and Loss are in accordance with INDAS Rule.

For and on behalf of the Board
Banwari Lal Mittal
 Chairman & Managing Director
 DIN: 00365809

Place : Kolkata
 Date : February 06, 2026

JANA SMALL FINANCE BANK
 (A Scheduled Commercial Bank)
 CIN No: L65923KA2006PLC040028
 Regd Office: The Rainway Business Park #10/1, 11/2, 12/2B, Off Dornier, Koramangala Inner Ring Road, Next to ECL, Challaighatta, Bengaluru - 560071

EXTRACTS OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025
 (₹ in 000s)

Particulars	Quarter Ended		Nine Months Ended		Year Ended
	31-12-2025	30-09-2025	31-12-2024	31-12-2024	
Total Income from Operations	1,62,88,593	1,55,22,491	1,35,48,159	4,69,72,588	4,05,24,916
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	96,942	749,907	10,53,359	18,66,099	35,38,395
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	96,942	749,907	10,53,359	18,66,099	35,38,395
Net Profit / (Loss) for the year (after tax) (after exceptional and/or extraordinary items)	96,942	749,907	11,06,601	18,66,099	37,79,402
Paid up Equity Share Capital	10,52,737	10,52,371	10,47,423	10,52,737	10,50,565
Reserves (excluding Employees Stock Option Reserve)	-	-	-	-	3,98,65,467
Networth	4,03,61,931	4,02,85,257	3,75,60,643	4,03,61,931	3,73,60,643
Paid up Debt Capital / Outstanding Debt	3,75,12,847	3,80,98,848	3,97,24,950	3,75,12,847	3,97,24,950
Outstanding Redeemable Preference Shares	-	-	-	-	3,86,68,171
Capital Adequacy Ratio (%)	19.17%	19.72%	18.39%	19.17%	18.39%
Debt Equity Ratio	0.87	0.89	1.00	0.87	1.00
Earnings Per Equity Share (face value of ₹ 10 per share) - Not annualised					
1. Basic (₹)	0.92	7.13	10.57	17.74	36.13
2. Diluted (₹)	0.92	7.09	10.49	17.66	35.84

Notes:
 1. The above publication is an extract of the detailed financial results filed with the Stock Exchange under Regulation 30, 33, 51 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
 2. The above results of the Bank have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on February 06, 2026.
 3. Previous year/period figures have been regrouped / reclassified, wherever necessary to conform with the current year/period presentation.
 4. The full format of financial results are available on Stock Exchange websites (www.bseindia.com and www.nseindia.com) and Bank's website (www.jana.bank.in)

For and on behalf of the Board of Directors
Ajay Karwal
 Managing Director & Chief Executive Officer

Bengaluru
 February 06, 2026.

NAPEROL INVESTMENTS LIMITED
 (formerly known as NATIONAL PEROXIDE LIMITED)
 Registered Office: Neville House, J. N. Heredia Marg, Ballard Estate, Mumbai-400001
 CIN : L66309MH1954PLC009254
 Tel No: (022) 66620000 • Website: www.naperolinvestments.com • Email: secretarial@naperol.com

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025
 (₹ in Lakhs)

Sr. No.	Particulars	Quarter ended		Nine months ended		Year ended
		31.12.2025	30.09.2025	31.12.2024	31.12.2024	
1	Total Revenue from Operations	102.19	294.00	139.05	718.89	339.95
2	Net Profit/(Loss) for the period (before Tax, Exceptional and Extraordinary Items)	(12.07)	4.14	(34.16)	2.56	105.99
3	Net Profit/(Loss) for the period before Tax (after Exceptional and Extraordinary Items)	(12.48)	4.14	(34.16)	2.15	105.99
4	Net Profit/(Loss) for the period after Tax (after Exceptional and Extraordinary Items)	(59.40)	(1.04)	(25.77)	(52.69)	74.73
5	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	6,258.23	(13,546.92)	(45,677.07)	7,056.60	31,485.87
6	Paid Up Equity Share Capital (face value of ₹10/- each)	574.70	574.70	574.70	574.70	574.70
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	-	1,15,781.39
8	Earnings per share (before and after extraordinary items) (face value of ₹10/- each) (Not annualised for the interim period)					
	(a) Basic	(1.03)	(0.02)	(0.45)	(0.92)	1.30
	(b) Diluted	(1.03)	(0.02)	(0.45)	(0.92)	1.30

Notes:
 1. The above is an extract of the detailed format of Unaudited Financial Results for the Quarter and Nine Months ended December 31, 2025 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of these results are available on the Stock Exchange's website (www.bseindia.com) and the Company's website (www.naperolinvestments.com).
 2. The said results were reviewed and recommended by the Audit Committee and approved by the Board of Directors in their meetings held on February 06, 2026.

For Naperol Investments Limited (formerly known as Peroxide Limited)
 Sd/-
Ness N Wadia
 Chairman
 DIN : 00036049

Place: Mumbai
 Date : February 06, 2026

FORTIS MALAR HOSPITALS LIMITED
 (CIN: L85110PB1989PLC045948)
 Regd. Office: Fortis Hospital, Sector 62, Phase - VIII, Mohali - 160062
 Tel : +91 172 5096001; Fax No : +91 172 5096002, Website: www.fortismalarhospital.com; Email: secretarial.malar@malarhospitals.in

STATEMENT OF UNAUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025
 (₹ in Lakhs except EPS)

PARTICULARS	CONSOLIDATED					
	UNAUDITED RESULTS			AUDITED RESULTS		
	FOR QUARTER ENDED		FOR NINE MONTHS ENDED	FOR QUARTER ENDED		FINANCIAL YEAR ENDED ON
	31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025
Total Revenue from Operations	0.25	2.50	-	4.80	-	-
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items#)	18.96	14.44	14.77	461.90	17.15	56.81
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items#)	18.96	14.44	14.77	461.90	17.15	56.81
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items#)	1.54	1.42	0.77	418.24	3.15	39.20
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	1.54	1.42	0.77	418.24	3.15	39.20
Paid - Up Equity Share Capital (Face Value of Rs. 10/- per share)	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year (as at March 31, 2025)	NA	NA	NA	NA	NA	1,145.21
Earnings Per Share (of Rs 10/- each) (for continuing and discontinued operations)						
(a) Basic (after exceptional items)	0.01	0.01	0.00	2.23	0.02	0.21
(b) Diluted (after exceptional items)	0.01	0.01	0.00	2.23	0.02	0.21

STANDALONE

PARTICULARS	UNAUDITED RESULTS			AUDITED RESULTS		
	FOR QUARTER ENDED		FOR NINE MONTHS ENDED	FOR QUARTER ENDED		FINANCIAL YEAR ENDED ON
	31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025
Total Revenue from Operations	-	-	-	-	-	-
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items#)	21.01	15.01	15.30	466.90	18.83	58.59
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items#)	21.01	15.01	15.30	466.90	18.83	58.59
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items#)	3.59	1.99	1.30	423.24	4.83	41.00
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	3.59	1.99	1.30	423.24	4.83	41.00
Paid - Up Equity Share Capital (Face Value of Rs. 10/- per share)	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year (as at March 31, 2025)	NA	NA	NA	NA	NA	1,120.71
Earnings Per Share (of Rs 10/- each) (for continuing and discontinued operations)						
(a) Basic (after exceptional items)	0.02	0.01	0.01	2.26	0.03	0.22
(b) Diluted (after exceptional items)	0.02	0.01	0.01	2.26	0.03	0.22

Notes:
 1. The above is an extract of the detailed format of Standalone and Consolidated Financial Results for the Quarter/ Nine Month ended on December 31, 2025 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Standalone and Consolidated Results for the Quarter/ nine months ended on December 31, 2025 are available on the Website of the Stock Exchange viz. www.bseindia.com and that of the company at www.fortismalarhospital.com.

Fortis Malar Hospitals Limited
 For and on Behalf of Board of Directors
 Sd/-
Bidish Chandra Paul
 Whole-time Director
 DIN: 08596135

Scan Me!
 Place : Gurugram
 Date : February 6, 2026

